ERAS

Erasca is executing a High-Conviction Price Discovery phase driven by breakthrough Phase 1 data for its pan-RAS molecular glue (ERAS-0015), which validated the pipeline and triggered a +90% rerating. The stock has demonstrated classic Institutional Absorption by digesting a $150M equity offering without breaking trend, signaling that smart money is positioning for 'best-in-class' RAS pathway dominance. This structural repricing is amplified by the 'Risk-On' macro regime, where falling yields embolden speculative flows into high-beta biotech assets exhibiting a 'Perfect Stack' setup.